A post-COVID patient, who is a known diabetic, develops unilateral facial pain and loosening of teeth. Which investigation would you do to confirm the diagnosis of this patient?

Correct Answer: C. Biopsy with histopathologic examination

This clinical presentation—unilateral facial pain, tooth loosening, and post-COVID status in a diabetic patient—is pathognomonic for Rhinocerebral Mucormycosis (RCM), an opportunistic fungal infection caused by Rhizopus species. The post-COVID immunosuppression combined with diabetes (especially if poorly controlled) creates the ideal milieu for angioinvasive mucormycosis. The fungus invades blood vessels, causing thrombosis, tissue necrosis, and palatal/alveolar bone destruction—hence tooth loosening. Unilateral facial pain reflects sinus involvement and orbital/intracranial extension risk. While imaging (CT/MRI) shows extent of disease, histopathologic examination with broad, non-septate hyphae and angioinvasion is the gold standard for definitive diagnosis. Tissue biopsy (from necrotic palate, nasal mucosa, or involved sinuses) allows identification of the causative organism and guides urgent antifungal therapy (liposomal amphotericin B). In India's post-COVID surge (2021–2022), mucormycosis became a notifiable disease; early histologic confirmation is critical because clinical suspicion alone can delay life-saving treatment. Biopsy is faster and more specific than culture, which may take weeks.

Why the other options are wrong

A. HbA1c — HbA1c assesses glycemic control and diabetes severity but does NOT diagnose the acute opportunistic infection causing facial pain and tooth loosening. While poor glycemic control is a risk factor for mucormycosis, measuring HbA1c does not confirm the diagnosis. This is an NBE trap: students may think 'diabetic patient → check HbA1c,' but the question asks for diagnosis confirmation, not risk stratification. B. Serum ferritin — Serum ferritin is elevated in post-COVID inflammation and iron overload but is non-specific and does NOT diagnose mucormycosis. Ferritin may be elevated in many post-COVID sequelae and infections, making it a red herring. This option exploits confusion between post-COVID inflammatory markers and the specific diagnosis of invasive fungal disease. D. MRI — MRI is essential for staging mucormycosis (assessing sinus, orbital, and intracranial involvement) and guiding surgical debridement, but it does NOT confirm the diagnosis. MRI shows extent of necrosis and edema but cannot differentiate mucormycosis from other invasive infections or malignancies. Histopathology is required for definitive diagnosis; imaging alone is insufficient and delays treatment.

High-Yield Facts

Mnemonics

MUCOR = Mucormycosis Red Flags Malignant course (rapid), Unilateral facial pain, Cavitary necrosis (palate/sinuses), Opportunistic (post-COVID, diabetes), Rhizopus (broad non-septate hyphae). Use this to recall the clinical triad and organism morphology. Biopsy > Imaging for Diagnosis Imaging = extent; Biopsy = diagnosis. MRI/CT show where the disease is; histology confirms what it is. In mucormycosis, you need both, but biopsy is diagnostic.

NBE Trap

NBE pairs post-COVID with diabetes to lure students into ordering metabolic tests (HbA1c, ferritin) rather than pursuing tissue diagnosis. The trap is confusing risk factors (diabetes, immunosuppression) with diagnostic confirmation (histopathology).

Clinical Pearl

In Indian hospitals during 2021–2022, mucormycosis became the "black fungus" epidemic in post-COVID diabetics. A patient presenting with unilateral facial pain and tooth loosening should raise immediate suspicion; bedside palatal examination for black eschar + urgent biopsy can save vision and life. Delay for imaging alone costs precious hours.

_Reference: Robbins Ch. 8 (Infectious Diseases); Harrison Ch. 207 (Mucormycosis); Park's Textbook of Preventive and Social Medicine (Post-COVID complications in India)_